To investigate sequential changes in laboratory markers after radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC) and the relationship of these changes to the severity of the underlying liver disease.
Methods
This retrospective analysis included 65 patients (44 males, 21 females) who underwent RFA of HCC. Hematologic and biochemical markers were assessed at the pre-RFA period and 1 day, 2-3 days, and 1-2 weeks after RFA. We classified the subjects into two groups: Child-Pugh A (n=41) and Child-Pugh B (n=24). The ablative margin volume (AMV) of each patient was measured. We analyzed the changes in laboratory profiles from the baseline, and investigated whether these laboratory changes were correlated with the AMV and the Child-Pugh classification.
Results
Most of the laboratory values peaked at 2-3 days after RFA. AMV was significantly correlated with changes in WBC count, hemoglobin level, and serum total bilirubin level (Pearson's correlation coefficient, 0.324-0.453; P<0.05). The alanine aminotransferase (ALT) level varied significantly over time (P=0.023).
Conclusions
Most of the measured laboratory markers changed from baseline, peaking at 2-3 days. The ALT level was the only parameter for which there was a significant difference after RFA between Child-Pugh A and B patients: it increased significantly more in the Child-Pugh A patients.
Citations
Citations to this article as recorded by
Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child–Pugh A category: A multicenter study Ying Zhang, Kazushi Numata, Kento Imajo, Haruki Uojima, Akihiro Funaoka, Satoshi Komiyama, Katsuaki Ogushi, Makoto Chuma, Kuniyasu Irie, Shigehiro Kokubu, Masato Yoneda, Takashi Kobayashi, Hisashi Hidaka, Taito Fukushima, Satoshi Kobayashi, Manabu Morimot Hepatology Research.2024; 54(12): 1174. CrossRef
Combination Therapy With Lenvatinib and Radiofrequency Ablation for Patients With Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh Class A Liver function: A Pilot Study Feiqian Wang, Kazushi Numata, Satoshi Komiyama, Haruo Miwa, Kazuya Sugimori, Katsuaki Ogushi, Satoshi Moriya, Akito Nozaki, Makoto Chuma, Litao Ruan, Shin Maeda Frontiers in Oncology.2022;[Epub] CrossRef
Hepatoprotective support during radiofrequency ablation in patients with colorectal liver metastases S. V. Vertyankin, O. M. Konopatskova Onkologiya. Zhurnal imeni P.A.Gertsena.2019; 8(5): 375. CrossRef
Feasibility of Percutaneous Intrahepatic Split by Microwave Ablation (PISA) After Portal Vein Embolization for Hypertrophy of Future Liver Remnant: The Radiological Stage-1 ALPPS Alessandro Lunardi, Rosa Cervelli, Duccio Volterrani, Saverio Vitali, Carlo Lombardo, Giulia Lorenzoni, Laura Crocetti, Irene Bargellini, Daniela Campani, Luca Emanuele Pollina, Roberto Cioni, Davide Caramella, Ugo Boggi CardioVascular and Interventional Radiology.2018;[Epub] CrossRef